Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rBIO-003
- Development stage
- Preclinical
- Lead developer
- R'BIO
- Modality
- Small Molecules
- Administration
- Intramuscular, Subcutaneous
01
Overview
rBIO-003 is an epinephrine biosimilar being developed by R'BIO for the treatment of anaphylaxis. It is produced using a proprietary high-yield microbial expression platform, which is intended to provide a scalable and cost-effective alternative to traditional epinephrine auto-injectors like the EpiPen. As a non-selective adrenergic agonist, rBIO-003 mimics the action of endogenous epinephrine by targeting alpha- and beta-adrenergic receptors. This action induces vasoconstriction to counter systemic hypotension, increases peripheral vascular resistance, and promotes bronchodilation to alleviate respiratory distress during severe allergic reactions. The drug is currently in the preclinical discovery stage.
- Other names
- Epinephrine biosimilarEpiPen alternative
Beyond the preview
Go deeper on rBIO-003.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rBIO-003.